Publications

1999

Leav I, Merk FB, Lee KF, Loda M, Mandoki M, McNeal JE, et al. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol. 1999;154(3):863-70.
Chiarle R, Podda A, Prolla G, Podack ER, Thorbecke GJ, Inghirami G. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol. 1999;163(1):194-205.
McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999;59(17):4291-6.
Crowson AN, Magro CM, Zahorchak R. Atypical pigmentary purpura: a clinical, histopathologic, and genotypic study. Hum Pathol. 1999;30(9):1004-12.

1998

Punch JD, Tono T, Qin L, Bishop DK, Bromberg JS. Tolerance induction by anti-CD2 plus anti-CD3 monoclonal antibodies: evidence for an IL-4 requirement. J Immunol. 1998;161(3):1156-62.
Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, Gutkind JS, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 1998;391(6662):86-9.
Macrì E, Loda M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev. 1998;17(4):337-44.
Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J Biol Chem. 1998;273(37):24057-64.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700